Skip to Main Content

Paper Details

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
J Med Chem
71
2018
ER, ER positive breast cancer, Estrogen, Estrogen Receptor, Estrogen Receptor Positive Breast Cancer, LSZ102, SERDs, aromatase, benzothiophene, breast cancer, estrogen, estrogen receptor, estrogen receptor alpha, estrogen receptor alpha (, fulvestrant, patients, steroid
Author NameAffiliation
Sunkyu KimNovartis Institutes for BioMedical Research, Inc.
Donald P McDonnellDuke University School of Medicine
  • 1 - 2

Datasets

Release 1.2